MA46466A - Formulations pharmaceutiques de protéines à viscosité réduite - Google Patents

Formulations pharmaceutiques de protéines à viscosité réduite

Info

Publication number
MA46466A
MA46466A MA046466A MA46466A MA46466A MA 46466 A MA46466 A MA 46466A MA 046466 A MA046466 A MA 046466A MA 46466 A MA46466 A MA 46466A MA 46466 A MA46466 A MA 46466A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
reduced viscosity
proteins
viscosity proteins
reduced
Prior art date
Application number
MA046466A
Other languages
English (en)
Inventor
William J Callahan
Twinkle R Christian
Christi L Clogston
Rahul Rajan Kaushik
Nazer Khalaf
Qahera Munaim
Alona Teran
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA46466A publication Critical patent/MA46466A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA046466A 2016-10-06 2017-10-06 Formulations pharmaceutiques de protéines à viscosité réduite MA46466A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404861P 2016-10-06 2016-10-06

Publications (1)

Publication Number Publication Date
MA46466A true MA46466A (fr) 2019-08-14

Family

ID=60294396

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046466A MA46466A (fr) 2016-10-06 2017-10-06 Formulations pharmaceutiques de protéines à viscosité réduite

Country Status (5)

Country Link
US (1) US11459401B2 (fr)
EP (1) EP3522918A1 (fr)
JP (2) JP7275027B2 (fr)
MA (1) MA46466A (fr)
WO (1) WO2018067987A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017000527A (es) * 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2017210360A1 (fr) 2016-05-31 2017-12-07 Cardiovax, Llc Procédés de diagnostic et de traitement du lupus érythémateux disséminé
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2019147824A1 (fr) 2018-01-26 2019-08-01 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
EP3810095A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2019246273A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un jak ou un autre inhibiteur de kinase
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2019246271A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020071876A1 (fr) * 2018-10-04 2020-04-09 삼성바이오에피스 주식회사 Trastuzumab à concentration élevée ayant une viscosité réduite ou agent de stabilisation de fragment de liaison à l'antigène associé
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
PH12022550167A1 (en) * 2019-08-16 2023-05-08 Regeneron Pharma High concentration anti-c5 formulations
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
CN111024863A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种雷莫芦单抗的肽图的测试方法
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112022026670A2 (pt) * 2020-07-13 2023-01-24 Merck Patent Gmbh Excipientes de redução da viscosidade e combinações dos mesmos para formulações de proteína altamente concentradas
EP4243793A4 (fr) 2020-11-10 2024-10-02 Medregen, LLC Préparations, procédés, nécessaires et formes posologiques
CA3204307A1 (fr) * 2020-12-17 2022-06-23 Astrazeneca Ab Formulations d'anticorps anti-il5r
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2024257040A1 (fr) * 2023-06-14 2024-12-19 Enzene Biosciences Limited Composition et formulations liquides stables comprenant des anticorps monoclonaux humanisés anti-récepteurs de l'interleukine 6 humaine (il-6)
CN120405149A (zh) * 2025-06-23 2025-08-01 美康生物科技股份有限公司 一种肝素结合蛋白检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ, インコーポレーテッド 5’修飾二環式核酸類似体
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2009131740A2 (fr) 2008-04-23 2009-10-29 Amgen Inc. Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2493507A4 (fr) 2009-10-30 2013-11-20 Merck Sharp & Dohme Antagonistes et variants ax213 et ax132 pcsk9
KR101614983B1 (ko) 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Hgh 및 rhigf―1의 조합물을 위한 제제
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
JP2014514275A (ja) 2011-03-10 2014-06-19 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
AU2013262611B2 (en) * 2012-05-18 2018-03-01 Genentech, Inc. High-concentration monoclonal antibody formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3193928A1 (fr) * 2014-08-06 2017-07-26 Rinat Neuroscience Corp. Méthodes destinées à réduire le cholestérol ldl
WO2016046684A1 (fr) * 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas

Also Published As

Publication number Publication date
WO2018067987A1 (fr) 2018-04-12
US11459401B2 (en) 2022-10-04
JP2023054369A (ja) 2023-04-13
JP2019530703A (ja) 2019-10-24
US20200024363A1 (en) 2020-01-23
JP7275027B2 (ja) 2023-05-17
EP3522918A1 (fr) 2019-08-14

Similar Documents

Publication Publication Date Title
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
EP3493799A4 (fr) Composition pharmaceutique decannabis
MA50541A (fr) Formulations pharmaceutiques
EP3509581A4 (fr) Formulations de (r
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
EP3493798A4 (fr) Composition pharmaceutique decannabis
MA46867A (fr) Formulations pharmaceutiques
EP3454899C0 (fr) Composition pharmaceutique
EP3364944C0 (fr) Compositions pharmaceutiques d'il-2
MA43705A (fr) Formulation pharmaceutique
MA42303A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (fr) Préparation pharmaceutique
EP3429589A4 (fr) Composition pharmaceutique du nilotinib
EP3454847A4 (fr) Formulations de médicaments améliorées
EP3402470A4 (fr) Composition pharmaceutique stable
MA47516A (fr) Composition pharmaceutique
EP3512521A4 (fr) Composition pharmaceutique de clozapine à libération prolongée
EP3383371A4 (fr) Formulation pharmaceutique
MA49837A (fr) Compositions pharmaceutiques
EP3646866A4 (fr) Préparation pharmaceutique
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (fr) Formulations pharmaceutiques
HUE069648T2 (hu) Gyógyszerészeti készítmény